Evelo Biosciences Inc

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors need to pay close attention to Evelo (EVLO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Evelo (EVLO) Stock?

Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2021 Results - Earnings Call Transcript

–EDP1815 Phase 2b data in psoriasis expected in 3Q 2021––Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021––Strengthened leadership team with appointment of Mark Plinio as Chief Commercial Officer––Multiple clinical data readouts expected over next 6-12 months––Management to host conference call at 8:30 a.m. ET–

Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 29, 2021, to report its second quarter 2021 financial results and discuss business highlights.

Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that given accelerating growth to later-stage development and the anticipated hiring and expansion of the Leadership Team, the Evelo Board of Directors has approved an inducement equity plan.

Evelo Biosciences Announces Inducement Award Plan for Expanding Leadership Team

CAMBRIDGE, Mass., June 01, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Mark Plinio as Chief Commercial Officer, effective June 14, 2021. Mr. Plinio brings significant pharmaceutical sales and marketing leadership to Evelo, including experience building and managing blockbuster brands through all stages of commercialization.

Evelo Biosciences Announces Appointment of Mark Plinio as Chief Commercial Officer

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will present at three upcoming virtual investor conferences in June:

Evelo Biosciences to Present at Upcoming Investor Conferences in June

Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing novel oral biologics intended to act on cells in the small intestine for immunomodulatory effects. Evelo's pipeline consists of four announced therapeutics (2 clinical-stage) across 4 indications (COVID-19, psoriasis, atopic dermatitis, general inflammation, and oncology) and two pre-IND exploratory research programs (neuro-inflammation and metabolic disorders).

Evelo Biosciences: Monoclonal Microbes Offer Novel Inflammatory Treatment With A Favorable Risk-Reward Profile

–On-track to initiate clinical development of EDP2939 in 2022–

Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939 at the American Association of Immunologists Meeting

Evelo Biosciences, Inc (EVLO) CEO Simba Gill on Q1 2021 Results - Earnings Call Transcript

–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting––Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors––Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets––Multiple clinical data readouts expected over next 18 months––Management to host conference call at 8:30 a.m. ET–

Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights

–Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting–

Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis

Ikena Oncology

180 Life Sciences 

Ikena Oncology, Inc. (NASDAQ: IKNA), 180 Life Sciences Corp. (NASDAQ: ATNF) and Evelo Biosciences, Inc. (NASDAQ: EVLO) are among the major biopharma movers of Monday. Ikena Oncology Gains On Fund Buying: Ikena Oncology, which listed its shares on the Nasdaq on March 26 following an initial public offering of 7.8125 million shares at $16 apiece, disclosed in a 13G filing, Citadel Advisors beneficially owned about 2,053,068 shares or a 6.6% stake in the company.

Why Ikena Oncology, Evelo Biosciences And 180 Life Sciences Are Rallying Today

CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12th 2:15 p.m. ET.

Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference

-- Collaboration expected to accelerate access to Evelo's lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in select developing markets and is Abdul Latif Jameel Health's first biotechnology licensing agreement –

Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2020 Results - Earnings Call Transcript

–Announced new positive data in human experimental model of inflammation of EDP1815––Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021––Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021––Up to 8 clinical data readouts expected over next 18 months––Management to host conference call at 8:30 a.m. ET–

Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, March 9, 2021 to report its fourth quarter and full year 2020 financial results and discuss business highlights.

Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021

Axcella Health Inc

Codiak Biosciences

Denali Therapeutics

Foghorn Therapeutics

Kaleido Biosciences Inc

Seres Therapeutics

Moderna

Rubius Therapeutics Inc

Sana Biotechnology

Sigilon Therapeutics

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The round included contributions from funds...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

Harley-Davidson

Texas Instruments

Alliance Data Systems

Bridge Bancorp

Brown & Brown

MSC Industrial Direct

Outlook Therapeutics Inc

Surgalign Holdings, Inc.

Vyne Therapeutics

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently.

Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More

CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock, at a public offering price of $15.00 per share, before underwriting discounts and commissions. Evelo also granted the underwriters a 30-day option, solely to cover over-allotments, if any, to purchase up to an additional 675,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $67,500,000 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Evelo.

Evelo Biosciences Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. Evelo expects to grant the underwriters a 30-day option, solely to cover over-allotments, if any, to purchase up to an additional $7.5 million of its common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by Evelo.

Evelo Biosciences Announces Proposed Public Offering of Common Stock

–EDP1815 was well tolerated, and showed clinically meaningful and consistent changes in all measured  physician-reported outcomes –

Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis

-- Expand EDP1815 Phase 2 program to include atopic dermatitis; interim clinical results expected in 1Q 2022 -- -- Accelerate delivery of interim clinical data from EDP1815 Phase 2 psoriasis trial to 2Q 2021; full dataset expected 2H 2021 --

Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones

CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which act in the small intestine to drive systemic effects, today announced the appointment of Jonathan Zung, Ph.D., as Chief Development Officer and a member of the Evelo Executive Team. Dr. Zung is an established industry veteran, who brings more than 25 years of global pharmaceutical development and commercialization experience to Evelo.

Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer

News for Evelo Biosciences Inc Stock (EVLO)